Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| CEM-SS | ED50 | 0.06 μM | Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay | [PMID: 15217281] |
| MT4 | EC50 | > 28.23 μM | Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay | [PMID: 26994843] |
| MT4 | CC50 | > 36 μM | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay | [PMID: 25707013] |
| MT4 | CC50 | > 36 μM | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay | [PMID: 25626145] |
| MT4 | EC50 | > 36 μM | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | [PMID: 25707013] |
| MT4 | EC50 | > 36 μM | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | [PMID: 25626145] |
| MT4 | CC50 | > 36 μM | Cytotoxicity against human MT4 cells after 5 days by MTT assay | [PMID: 24239481] |
| MT4 | EC50 | > 36 μM | Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay | [PMID: 24239481] |
| MT4 | CC50 | > 36.19 μM | Cytotoxicity against human MT4 cells after 5 days by MTT assay | [PMID: 22591854] |
| MT4 | EC50 | > 36.19 μM | Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | [PMID: 22591854] |
| MT4 | CC50 | > 36.2 μM | Cytotoxicity against human MT4 cells after 5 days by MTT assay | [PMID: 22405288] |
| MT4 | EC50 | > 36.2 μM | Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay | [PMID: 22405288] |
| MT4 | EC50 | > 43.81 μM | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | [PMID: 25240095] |
| MT4 | CC50 | > 43.81 μM | Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay | [PMID: 25240095] |
| MT4 | EC50 | 0.027 μM | Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay | [PMID: 26994843] |
| MT4 | EC50 | 0.06 μM | Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | [PMID: 21872971] |
| MT4 | EC50 | 0.13 μM | Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay | [PMID: 24239481] |
| MT4 | EC50 | 0.54 μM | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | [PMID: 25707013] |
| MT4 | EC50 | 0.66 μM | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | [PMID: 25240095] |
19 records · Scroll to view more